Unable to load price data. Sorry.


AXIM Biotechnologies, Inc. (NASDAQ OTHER:AXIM)

CAPS Rating: 1 out of 5

Unable to load market data for this Ticker. Sorry.



How do you think NASDAQ OTHER:AXIM will perform against the market?

Add Stock to CAPS Watchlist

All Players

4 Outperform
41 Underperform

All-Star Players

1 Outperform
33 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ OTHER:AXIM Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Bigsef77 (67.64)
Submitted April 05, 2018

Better to be lucky than good & I got lucky. AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew and MedChew Products Throughout South KoreaGlobeNewswire•April 3, 2018NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- AXIM®… More

TSIF (99.98)
Submitted November 09, 2016

Jed71 wrote this one up.http://caps.fool.com/Pitch/AXIM/7664077/good-grief-another-really-bad-.aspxOTC $190M market cap. 6 employees.Timing for them was great as Cannabis stocks soared pre-election, even the ones without a product or any expectations… More



Fools bearish on NASDAQ OTHER:AXIM are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about AXIM.


Member Avatar jed71 (99.64) Submitted: 2/4/2019 11:05:23 AM : Underperform Start Price: $1.38 NASDAQ OTHER:AXIM Score: +1.12

I have pitched this one before, and nothing has markedly changed to improve its situation. There's really no need for me to add more other than to reference my old pitch:



Member Avatar SmartAce (99.97) Submitted: 1/23/2019 3:22:37 PM : Underperform Start Price: $1.11 NASDAQ OTHER:AXIM Score: -21.48

In the shower you discover a dial on your neck. It's turned to 7; there's no indication of what it controls. You set it to 8 and get dressed.


Member Avatar Bigsef77 (67.64) Submitted: 4/5/2018 3:16:36 PM : Outperform Start Price: $3.85 NASDAQ OTHER:AXIM Score: -74.62

Better to be lucky than good & I got lucky.

AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew and MedChew Products Throughout South Korea
GlobeNewswire•April 3, 2018

NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Memo of Understanding (“MOU”) with a leading Korean specialty pharmaceutical company for the commercialization of two of the Company’s cannabinoid-based propriety pharmaceutical applications, CanChew+™ and MedChew®, in South Korea.

The MOU, which was reached on March 30, 2018, outlines how distribution partner will monitor the regulatory environment in the country and work with the South Korean Ministry of Food and Drug Safety (“MFDS”) in order to register the products for sale to the more than 50 million people in South Korea.

“Preparation for international market expansion is vital at this stage of our company’s growth,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “As the regulations and public perception of cannabinoid-based therapeutics shift toward acceptance throughout the world, AXIM will be ready to capture as much market share as possible for treatments of various indications. We have seen promising results in our initial studies that we hope to bring to a worldwide audience upon approval from regulatory officials.”

The Company’s flagship CanChew pharmaceutical program currently is currently undergoing human clinical trials for treatment of Irritable Bowel Syndrome (“IBS”). The MedChew program will feature products targeting treatment for pain and spasticity in Multiple Sclerosis patients as well as a bioequivalent product to Marinol using dronabinol for treatment of nausea associated with cancer treatment. Additional targeted indications for these programs include drug-related psychosis, Restless Leg Syndrome, Parkinson’s disease, and dementia,


Find the members with the highest scoring picks in AXIM.

Score Leader


whatsthepoint (99.98) Score: +179.01

The Score Leader is the player with the highest score across all their picks in AXIM.

Member Name Member
Call Time
Score Commentary
germanjuggler 68.85 1/11/2017 8/7/2018 Underperform 1Y $11.90 -87.56% +29.12% +116.68 0 Comment
tsperbeck 99.59 12/1/2016 Underperform 1Y $8.89 -83.35% +33.22% +116.58 0 Comment
Doppelganger 43.77 1/10/2017 Underperform 5Y $11.40 -87.02% +29.18% +116.20 0 Comment
hesterprin 61.73 12/1/2016 11/9/2017 Underperform 1Y $8.50 -82.59% +32.42% +115.00 0 Comment
warrenout 98.99 11/22/2016 Underperform 5Y $8.00 -81.50% +32.55% +114.05 0 Comment
RES7 98.29 12/8/2016 Underperform 5Y $9.16 -83.84% +30.15% +113.99 0 Comment
gcaderas 79.69 4/18/2017 Underperform 5Y $13.20 -88.79% +25.06% +113.84 0 Comment
patatepoil6 99.87 12/16/2016 Underperform 5Y $8.88 -83.32% +29.32% +112.65 0 Comment
Mikimikkers 97.78 11/18/2016 Underperform 1Y $6.85 -78.39% +33.42% +111.81 0 Comment
downwithpumpers 99.23 5/5/2017 Underperform 5Y $10.95 -86.48% +22.31% +108.79 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AXIM.